← Back

Conduit Pharmaceuticals Inc.

CDT Equity Inc. is a data-driven biopharmaceutical company focused on identifying, enhancing, and monetizing therapeutic assets. Its pipeline includes AZD1656, a glucokinase activator in Phase II trials for autoimmune disorders such as uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, in Phase I trials for Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I trials for idiopathic male infertility. The company also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases, and animal health. Formerly known as Conduit Pharmaceuticals Inc., it changed its name to CDT Equity Inc. in August 2025, was founded in 2019, and is based in Naples, Florida.

Price · split & dividend adjusted
News & notes moving CDT
CDT

CDT Equity Inc. approves 1-for-10 reverse stock split

CDT Equity Inc. has approved a 1-for-10 reverse stock split to maintain Nasdaq listing compliance. The split becomes effective July 17, 2026, at 5:00 pm Eastern Time, with shares expected to trade on a split-adjusted basis on Nasdaq under the ticker CDT starting July 20, 2026. Every 10 outstanding shares will be combined into one, reducing the share count to approximately 631,077, while the par value remains $0.0001 per share. No fractional shares will be issued; instead, stockholders will receive a proportional cash payment. The company's transfer agent, Continental Stock Transfer & Trust Co., will handle the exchange, and stockholders holding shares in brokerage accounts or book-entry form need take no action.
GlobeNewswire·64dRead more →